Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that regularly issues news on its operations, financial performance, and corporate developments. The company focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, and its updates reflect activity across these areas.
On this page, readers can follow ITGR news related to quarterly earnings, product line performance, and outlooks that Integer provides through press releases furnished with Form 8-K filings. These releases often include discussions of sales trends in Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, along with non-GAAP financial measures such as adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted earnings per share.
Integer’s news flow also covers strategic and governance events, such as leadership transitions, board appointments, and capital allocation decisions. Recent examples include the appointment of a new President and Chief Executive Officer, the election of a new director with extensive medical device industry experience, and the authorization of a share repurchase program by the Board of Directors.
In addition, Integer publishes updates on technology and market-facing activities, such as participation in medical society meetings and healthcare investor conferences. The company has highlighted innovations in neuromodulation and miniaturized active implantable medical devices, including high-performance batteries and integrated implantable pulse generator and lead systems, as well as its Xcellion Gen 3 fast charge lithium ion battery technology.
Investors and observers can use this news page to monitor how Integer communicates its strategy, product line dynamics, financing actions, and role as a CDMO in the cardiac rhythm management, neuromodulation, and cardio and vascular markets.
Integer Holdings Corporation (NYSE:ITGR) reported a 19% sales growth in Q4 2022, reaching $372 million, with annual sales up 13% to $1.376 billion. Despite the growth, GAAP income decreased 15% to $17 million in Q4 and 30% to $65 million for the full year. Adjusted net income rose 12% to $37 million in Q4. The company expects 7% to 9% sales growth in 2023, driven by improving operational efficiencies and capacity investments. Debt increased to $925 million, linked to the Aran Biomedical acquisition. Integer remains optimistic about sustained above-market growth despite challenges in the supply chain.
Integer Holdings Corporation (NYSE: ITGR) announced the successful closing of its $500 million convertible senior notes offering, reducing its floating-rate debt. The offering was oversubscribed, increasing from $375 million to $500 million due to strong investor demand. The new 2.125% notes, due 2028, will decrease annual interest expenses by approximately $15 million, enhancing earnings immediately in 2023. The proceeds will repay existing debt, aligning the maturity of the notes with current obligations. The enhanced conversion structure aims to minimize future dilution, with a conversion price at a significant premium to the current stock price.
Integer Holdings Corporation (NYSE: ITGR) will exhibit at the MD&M West Exposition in Anaheim, California, from Feb. 7-9, 2023. At booth #1759, Integer will showcase its end-to-end medical device design, development, and manufacturing solutions, enhanced by the acquisitions of Aran Biomedical and Oscor. Key innovations include the new Gen 2 CFx Battery Technology, advanced electrophysiology solutions, and a comprehensive suite of neurovascular and structural heart capabilities. President Payman Khales emphasized the company’s focus on expanding its global footprint and capabilities to meet rising customer demand.
Integer Holdings Corporation (NYSE: ITGR) has announced the pricing of $435 million in 2.125% convertible senior notes due 2028, up from an initial size of $375 million. The offering, set to close on February 3, 2023, comes with an option for purchasers to acquire an additional $65 million. The net proceeds, estimated at $422.2 million, will primarily be used to pay off existing borrowings and expenses associated with capped call transactions valued at $30.5 million. The conversion price of $87.20 per share reflects a 32.5% premium over the January 31 closing price of $65.81. This move aims to reduce exposure to floating rate debt.
Integer Holdings Corporation (ITGR) has announced its intention to offer $375 million in convertible senior notes due February 15, 2028, with an option for purchasers to acquire an additional $56.25 million. Proceeds from this offering will be allocated to capped call transactions and the repayment of borrowings under the Company’s term B loan. This move aims to reduce the company’s exposure to floating-rate debt and stabilize cash interest expenses. The notes will be convertible under specified conditions and may lead to potential dilution of common stock.
Integer Holdings Corporation (NYSE: ITGR) announced preliminary financial results for Q4 and full year 2022. Q4 sales are projected between $370 million and $372 million, an increase of 18% to 19% year-over-year, with organic growth of 12% to 13%. GAAP operating income is expected to rise by 25% to 29% to $36 to $37 million. For the full year, sales are projected at $1.374 to $1.376 billion, a 13% increase. However, GAAP operating income is anticipated to decrease by 11% to $120 to $121 million. The company will provide detailed 2023 guidance during the earnings call on February 16, 2023.
Integer Holdings Corporation (NYSE: ITGR) will showcase its advanced capabilities in neuromodulation at the 26th North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 12-14, 2023. The company, a leader in medical device outsourcing, invites attendees to visit booth #525 to explore new implantable devices resulting from the Oscor acquisition in December 2021. Integer will also present its Xcellion Gen 3 Fast Charge Lithium Ion battery technology, offering best-in-class runtime with recharges in just 30 minutes, emphasizing innovation in active implantables.
Integer Holdings Corporation (NYSE:ITGR) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022. CEO Joe Dziedzic will present on November 30, 2022, at 8:10 a.m. ET. The presentation, including a Q&A session, will be available via live webcast on Integer's website, with replays archived for 30 days. Integer is a leading medical device outsource manufacturer serving various markets, including cardiac and orthopedics, and develops specialized batteries for high-end applications.
Integer Holdings Corporation (NYSE:ITGR) reported a 12% increase in sales to $343 million for Q3 2022, but GAAP net income fell 27% to $16 million. Non-GAAP adjusted net income also declined by 9%. Debt increased by $111 million to $939 million, driven by the Aran Biomedical acquisition, leading to a leverage ratio of 3.8 times adjusted EBITDA. Despite challenges in supply chain performance, management anticipates 7% to 9% growth in revenue for 2023, with margin expansion expected. Organic sales growth outlook for 2022 is 4% to 6%.
Integer Holdings Corporation (NYSE: ITGR) provided a revised 2022 outlook amidst ongoing supply chain challenges and strong customer demand. Q3 sales were negatively impacted by $15 million due to supplier issues, leading to an expected $25 million decrease in full-year operating income. Despite higher manufacturing costs, Integer is reducing SG&A expenses by $8 million annually. The 2023 sales outlook remains optimistic at 7-9% growth, driven by strong demand and a robust backlog.